Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Med Schools Improve Conflict Of Interest Policies, But Widespread Problems Remain
According to the latest ratings of two watchdog groups, medical schools are "improving their conflict-of-interest policies to police their ties with drug and medical-device makers. But more than half the schools still have inadequate policies or no policies at all," the Wall Street Journal"s Health Blog reports. The American Medical Student Association and the Pew Prescription Project said the number of schools earning top marks had more than doubled, in part because of pressure from lawmakers like Sen. Charles Grassley, R-Iowa. But, "there are a lot of schools that are yet to look seriously at these issues," the director of the Pew project said.
generic viagra online
FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair
The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma.
News of the day
Partner Relationship As A Buffer Against Stress
A good partner relationship can act as a buffer for those exposed to work-related stress.
Nutrition

FDA Advisory Committee Votes In Favor Of Zyprexa For Two Adolescent Indications

Lilly) This press release contains forward-looking statements about Zyprexa. These statements reflect management"s current beliefs; however, as with any pharmaceutical product there are risks and uncertainties in the process of research and development, regulatory review, and commercialization. There is no guarantee that Zyprexa will be approved for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents, or that, if approved, it will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly"s filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements. References (1) The National Institute for Mental Illness. "About Mental Illness: Early Onset Schizophrenia." (2) The Child & Adolescent Bipolar Foundation. About Pediatric Bipolar Disorder. (3) The National Institute of Mental Health. About Mental Illness: Bipolar Disorder. (4) The National Institute of Mental Health. What is Schizophrenia? (5) Loranger, AW (1984): Sex difference in age of onset of schizophrenia. Archives of General Psychiatry; 41: 157-161 (6) Fleischhaker, C. et al. Long-term Course of Adolescent Schizophrenia. Schizophrenia Bulletin 2005 31(3):769-780; doi:10.1093/schbul/sbi014. (7) Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun;62(6):617-27. (8) Mauricio Tohen et al. (2007). Olanzapine versus Placebo in the Treatment of Adolescents with Bipolar Mania. Am J Psychiatry 2007, 164: 1547-1556 (9) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, pg. 385. (10) Korn, M. (2002). Building Foundations Toward Recovery in Bipolar Disorder. How Prevalent are Mood Disorders in Children and Adolescents? (11) Axelson D et al. (2006). Phenomenology of children and adolescents with bipolar spectrum disorders. Archives of General Psychiatry; 63(10):1139-48. Eli Lilly and Company

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009